CNMDNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
CONMED Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$46.05−0.67 (-1.43%)
Close on Oct 19, 2026
- Market cap
- $1.39B
- P/E (TTM)
- 24.9
- Dividend yield
- 1.30%
CONMED Corp revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General Surgery | $191.17M | $169.38M | $215.82M | $199.73M | $201.61M | $182.97M | $206.94M | $186.16M | $192.56M | $177.36M | $190.52M | $179.91M | 55.7% | -5.2% |
| Orthopedic Surgery | $152.32M | $147.66M | $157.38M | $138.19M | $140.73M | $138.29M | $139.00M | $130.54M | $139.54M | $134.91M | $136.53M | $124.67M | 44.3% | +8.2% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $175.39M | $173.06M | $206.24M | $193.98M | $190.61M | $183.76M | $203.30M | $183.15M | $185.37M | $176.41M | $190.38M | $170.52M | 51.1% | -8.0% |
| Europe, Middle East & Africa | $76.15M | $69.14M | $74.52M | $58.68M | $67.78M | $63.68M | $63.00M | $55.52M | $63.69M | $60.86M | $60.52M | $51.44M | 22.2% | +12.3% |
| Asia Pacific | $57.16M | $41.96M | $59.10M | $53.83M | $52.08M | $43.71M | $49.68M | $49.21M | $51.41M | $44.39M | $45.40M | $53.28M | 16.6% | +9.7% |
| Americas (excluding the United States) | $34.80M | $32.90M | $33.34M | $31.44M | $31.88M | $30.11M | $29.96M | $28.82M | $31.64M | $30.62M | $30.74M | $29.33M | 10.1% | +9.2% |
From the segment and revenue-disaggregation notes of Conmed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.